Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Mycenax Biotech
- 08 Mar 2019 Status changed from recruiting to discontinued.
- 26 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.